Curve Biosciences has developed a "Whole-Body Intelligence" platform using cfDNA from blood to monitor chronic diseases, starting with the liver. Focused on liver cirrhosis and MASH, the company aims to aid in treatment decisions and plans to expand into monitoring other organs.
Zealand Pharma posted modest efficacy data from its Phase II petrelintide trial in obesity patients, while highlighting promising tolerability for the drug as the firm looks to enter the highly competitive obesity drug market.
While analysts highlighted that petrelintide’s weight loss numbers came in below their expectations, the drug’s tolerability, similar to placebo, could...
Curve Biosciences has developed a "Whole-Body Intelligence" platform using cfDNA from blood to monitor chronic diseases, starting with the liver. Focused on liver cirrhosis and MASH, the company aims to aid in treatment decisions and plans to expand into monitoring other organs.
The gut’s microbiome will shape future medical advances, offering personalized therapies and prevention strategies for a wide range of diseases.
A look at new research on the cardiovascular effects of ADHD medications and what it means for clinical care. This article explores the latest clinical and epidemiological research on the cardiovascular effects of medications commonly prescribed for ADHD, examining potential heart-related risks, underlying mechanisms, and their implications for patient safety, clinical decision-making, and long-term treatment strategies across diverse age groups and risk profiles.
L’Oréal and Galderma have signed a memorandum of understanding to collaborate on complementary research projects to discover ‘new avenues and accelerate innovation’ in the field of dermatology. L’Oreal has arranged to purchase a 10% stake in its partner.
The gut’s microbiome will shape future medical advances, offering personalized therapies and prevention strategies for a wide range of diseases.
A look at new research on the cardiovascular effects of ADHD medications and what it means for clinical care. This article explores the latest clinical and epidemiological research on the cardiovascular effects of medications commonly prescribed for ADHD, examining potential heart-related risks, underlying mechanisms, and their implications for patient safety, clinical decision-making, and long-term treatment strategies across diverse age groups and risk profiles.
